{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:49:59Z","timestamp":1791989399427,"version":"4.4.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pulmonary arterial hypertension (PAH) is a devastating disease with poor prognosis and limited therapeutic options. We screened for pathways that may be responsible for the abnormal phenotype of pulmonary arterial smooth muscle cells (PASMCs), a major contributor of PAH pathobiology, and identified cyclin-dependent kinases (CDKs) as overactivated kinases in specimens derived from patients with idiopathic PAH. This increased CDK activity is confirmed at the level of mRNA and protein expression in human and experimental PAH, respectively. Specific CDK inhibition by dinaciclib and palbociclib decreases PASMC proliferation via cell cycle arrest and interference with the downstream CDK-Rb (retinoblastoma protein)-E2F signaling pathway. In two experimental models of PAH (i.e., monocrotaline and Su5416\/hypoxia treated rats) palbociclib reverses the elevated right ventricular systolic pressure, reduces right heart hypertrophy, restores the cardiac index, and reduces pulmonary vascular remodeling. These results demonstrate that inhibition of CDKs by palbociclib may be a therapeutic strategy in PAH.<\/jats:p>","DOI":"10.1038\/s41467-019-10135-x","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T10:04:09Z","timestamp":1558087449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension"],"prefix":"10.1038","volume":"10","author":[{"given":"Astrid","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz Christian","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Yerabolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baktybek","family":"Kojonazarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate Christiane","family":"Schlueter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Neubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Jonigk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Baal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dorfmuller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0440-8831","authenticated-orcid":false,"given":"Soni Savai","family":"Pullamsetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2675-3871","authenticated-orcid":false,"given":"Norbert","family":"Weissmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein-Ardeschir","family":"Ghofrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Grimminger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1946-0894","authenticated-orcid":false,"given":"Werner","family":"Seeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-6970","authenticated-orcid":false,"given":"Ralph Theo","family":"Schermuly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"key":"10135_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2011.87","volume":"8","author":"RT Schermuly","year":"2011","unstructured":"Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R. & Grimminger, F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443\u2013455 (2011).","journal-title":"Nat. Rev. Cardiol."},{"key":"10135_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1183\/09059180.00007513","volume":"22","author":"C Guignabert","year":"2013","unstructured":"Guignabert, C. et al. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur. Respir. Rev. 22, 543\u2013551 (2013).","journal-title":"Eur. Respir. Rev."},{"key":"10135_CR3","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1164\/rccm.200709-1369PP","volume":"178","author":"PR Rai","year":"2008","unstructured":"Rai, P. R. et al. The cancer paradigm of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 178, 558\u2013564 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10135_CR4","doi-asserted-by":"publisher","first-page":"D4","DOI":"10.1016\/j.jacc.2013.10.025","volume":"62","author":"RM Tuder","year":"2013","unstructured":"Tuder, R. M. et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J. Am. Coll. Cardiol. 62, D4\u2013D12 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"10135_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1055\/s-0033-1356494","volume":"34","author":"L Godinas","year":"2013","unstructured":"Godinas, L. et al. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin. Respir. Crit. Care Med. 34, 714\u2013724 (2013).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10135_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijcard.2010.07.003","volume":"147","author":"S Sakao","year":"2011","unstructured":"Sakao, S. & Tatsumi, K. Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities. Int. J. Cardiol. 147, 4\u201312 (2011).","journal-title":"Int. J. Cardiol."},{"key":"10135_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1165\/ajrcmb.25.5.4592","volume":"25","author":"BW Fouty","year":"2001","unstructured":"Fouty, B. W. et al. p27(Kip1) is important in modulating pulmonary artery smooth muscle cell proliferation. Am. J. Respir. Cell Mol. Biol. 25, 652\u2013p658 (2001).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10135_CR8","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1021\/cb4003283","volume":"8","author":"MP Martin","year":"2013","unstructured":"Martin, M. P., Olesen, S. H., Georg, G. I. & Schonbrunn, E. Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8, 2360\u20132365 (2013).","journal-title":"ACS Chem. Biol."},{"key":"10135_CR9","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.phrs.2016.03.012","volume":"107","author":"R Roskoski Jr.","year":"2016","unstructured":"Roskoski, R. Jr. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs. Pharmacol. Res. 107, 249\u2013275 (2016).","journal-title":"Pharmacol. Res."},{"key":"10135_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153\u2013166 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"10135_CR11","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1016\/j.bmcl.2015.05.100","volume":"25","author":"C Sanchez-Martinez","year":"2015","unstructured":"Sanchez-Martinez, C., Gelbert, L. M., Lallena, M. J. & de Dios, A. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. Bioorg. Med. Chem. Lett. 25, 3420\u20133435 (2015).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10135_CR12","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna, S. & Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547\u2013566 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10135_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/srep29090","volume":"6","author":"Z Chen","year":"2016","unstructured":"Chen, Z. et al. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity. Sci. Rep. 6, 29090 (2016).","journal-title":"Sci. Rep."},{"key":"10135_CR14","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/leu.2015.31","volume":"29","author":"J Flynn","year":"2015","unstructured":"Flynn, J. et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 29, 1524\u20131529 (2015).","journal-title":"Leukemia"},{"key":"10135_CR15","doi-asserted-by":"publisher","first-page":"56864","DOI":"10.18632\/oncotarget.10870","volume":"7","author":"S Rajput","year":"2016","unstructured":"Rajput, S. et al. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer. Oncotarget 7, 56864\u201356875 (2016).","journal-title":"Oncotarget"},{"key":"10135_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/ml100051d","volume":"1","author":"K Paruch","year":"2010","unstructured":"Paruch, K. et al. Discovery of dinaciclib (SCH 727965): A potent and selective inhibitor of cyclin-dependent kinases. ACS Med. Chem. Lett. 1, 204\u2013208 (2010).","journal-title":"ACS Med. Chem. Lett."},{"key":"10135_CR17","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry, D. et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol. Cancer Ther. 9, 2344\u20132353 (2010).","journal-title":"Mol. Cancer Ther."},{"key":"10135_CR18","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000447417","volume":"11","author":"J Ettl","year":"2016","unstructured":"Ettl, J. Palbociclib: First CDK4\/6 inhibitor in clinical practice for the treatment of advanced HR-positive breast cancer. Breast Care 11, 174\u2013176 (2016).","journal-title":"Breast Care"},{"key":"10135_CR19","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1007\/s00216-010-3784-7","volume":"397","author":"SR Piersma","year":"2010","unstructured":"Piersma, S. R., Labots, M., Verheul, H. M. & Jimenez, C. R. Strategies for kinome profiling in cancer and potential clinical applications: chemical proteomics and array-based methods. Anal. Bioanal. Chem. 397, 3163\u20133171 (2010).","journal-title":"Anal. Bioanal. Chem."},{"key":"10135_CR20","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1002\/pmic.201100296","volume":"11","author":"R Arsenault","year":"2011","unstructured":"Arsenault, R., Griebel, P. & Napper, S. Peptide arrays for kinome analysis: new opportunities and remaining challenges. Proteomics 11, 4595\u20134609 (2011).","journal-title":"Proteomics"},{"key":"10135_CR21","doi-asserted-by":"publisher","first-page":"e116388","DOI":"10.1371\/journal.pone.0116388","volume":"9","author":"JC Anderson","year":"2014","unstructured":"Anderson, J. C. et al. Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine. PLoS ONE 9, e116388 (2014).","journal-title":"PLoS ONE"},{"key":"10135_CR22","doi-asserted-by":"publisher","first-page":"e0139267","DOI":"10.1371\/journal.pone.0139267","volume":"10","author":"JC Anderson","year":"2015","unstructured":"Anderson, J. C. et al. High throughput kinomic profiling of human clear cell renal cell carcinoma identifies kinase activity dependent molecular subtypes. PLoS ONE 10, e0139267 (2015).","journal-title":"PLoS ONE"},{"key":"10135_CR23","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1097\/QAD.0000000000000399","volume":"28","author":"E Pauls","year":"2014","unstructured":"Pauls, E. et al. Palbociclib, a selective inhibitor of cyclin-dependent kinase4\/6, blocks HIV-1 reverse transcription through the control of sterile alpha motif and HD domain-containing protein-1 (SAMHD1) activity. Aids 28, 2213\u20132222 (2014).","journal-title":"Aids"},{"key":"10135_CR24","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.1128\/MCB.21.12.4032-4045.2001","volume":"21","author":"Z Sever-Chroneos","year":"2001","unstructured":"Sever-Chroneos, Z. et al. Retinoblastoma tumor suppressor protein signals through inhibition of cyclin-dependent kinase 2 activity to disrupt PCNA function in S phase. Mol. Cell. Biol. 21, 4032\u20134045 (2001).","journal-title":"Mol. Cell. Biol."},{"key":"10135_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.bioorg.2011.07.004","volume":"39","author":"PA Schwartz","year":"2011","unstructured":"Schwartz, P. A. & Murray, B. W. Protein kinase biochemistry and drug discovery. Bioorg. Chem. 39, 192\u2013210 (2011).","journal-title":"Bioorg. Chem."},{"key":"10135_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400\u2013414 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"10135_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/nrc2347","volume":"8","author":"IM Chu","year":"2008","unstructured":"Chu, I. M., Hengst, L. & Slingerland, J. M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 8, 253\u2013267 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"10135_CR28","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/onc.2010.614","volume":"30","author":"C Romagosa","year":"2011","unstructured":"Romagosa, C. et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 30, 2087\u20132097 (2011).","journal-title":"Oncogene"},{"key":"10135_CR29","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/01.CIR.101.17.2022","volume":"101","author":"FC Tanner","year":"2000","unstructured":"Tanner, F. C. et al. Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 101, 2022\u20132025 (2000).","journal-title":"Circulation"},{"key":"10135_CR30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1161\/01.RES.82.3.396","volume":"82","author":"FC Tanner","year":"1998","unstructured":"Tanner, F. C. et al. Expression of cyclin-dependent kinase inhibitors in vascular disease. Circ. Res. 82, 396\u2013403 (1998).","journal-title":"Circ. Res."},{"key":"10135_CR31","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1164\/rccm.201106-1093OC","volume":"185","author":"SS Pullamsetti","year":"2012","unstructured":"Pullamsetti, S. S. et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am. J. Respir. Crit. Care Med. 185, 409\u2013419 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10135_CR32","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1183\/13993003.00773-2015","volume":"48","author":"S Dabral","year":"2016","unstructured":"Dabral, S. et al. Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. Eur. Respir. J. 48, 1137\u20131149 (2016).","journal-title":"Eur. Respir. J."},{"key":"10135_CR33","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1517\/13543784.2014.948152","volume":"23","author":"C Criscitiello","year":"2014","unstructured":"Criscitiello, C., Viale, G., Esposito, A. & Curigliano, G. Dinaciclib for the treatment of breast cancer. Expert Opin. Investig. drugs 23, 1305\u20131312 (2014).","journal-title":"Expert Opin. Investig. drugs"},{"key":"10135_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar, U., Witkiewicz, A. K., Turner, N. C. & Knudsen, E. S. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat. Rev. Drug Discov. 14, 130\u2013146 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10135_CR35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: From Discovery to Therapy. Cancer Discov. 6, 353\u2013367 (2016).","journal-title":"Cancer Discov."},{"key":"10135_CR36","first-page":"417","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary, B., Finn, R. S. & Turner, N. C. Treating cancer with selective CDK4\/6 inhibitors. Nature reviews. Clin. Oncol. 13, 417\u2013430 (2016).","journal-title":"Clin. Oncol."},{"key":"10135_CR37","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1634\/theoncologist.2016-0097","volume":"21","author":"S Verma","year":"2016","unstructured":"Verma, S. et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive\/HER2-negative advanced metastatic breast cancer: Detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). Oncologist 21, 1165\u20131175 (2016).","journal-title":"Oncologist"},{"issue":"2","key":"10135_CR38","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(18)30001-9","volume":"19","author":"Luca Gianni","year":"2018","unstructured":"Gianni, L. et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. The Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(18)30001-9 (2018).","journal-title":"The Lancet Oncology"},{"key":"10135_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn, R. S. et al. The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol. 16, 25\u201335 (2015).","journal-title":"Lancet Oncol."},{"key":"10135_CR40","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1158\/1535-7163.MCT-16-0300","volume":"15","author":"P Chen","year":"2016","unstructured":"Chen, P. et al. Spectrum and degree of CDK drug interactions predicts clinical performance. Mol. cancer Ther. 15, 2273\u20132281 (2016).","journal-title":"Mol. cancer Ther."},{"key":"10135_CR41","first-page":"1864107","volume":"2018","author":"J Xu","year":"2018","unstructured":"Xu, J. et al. Glucagon-like peptide-1 mediates the protective effect of the dipeptidyl peptidase IV inhibitor on renal fibrosis via reducing the phenotypic conversion of renal microvascular cells in monocrotaline-treated rats. BioMed. Res. Int. 2018, 1864107 (2018).","journal-title":"BioMed. Res. Int."},{"key":"10135_CR42","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.etap.2016.07.002","volume":"46","author":"Z Zheng","year":"2016","unstructured":"Zheng, Z. et al. Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NFkappaB, Egr1, Nrf2, MAPKs and PI3K signals. Environ. Toxicol. Pharmacol. 46, 80\u201389 (2016).","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10135_CR43","doi-asserted-by":"publisher","first-page":"L363","DOI":"10.1152\/ajplung.00212.2011","volume":"302","author":"JG Gomez-Arroyo","year":"2012","unstructured":"Gomez-Arroyo, J. G. et al. The monocrotaline model of pulmonary hypertension in perspective. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L363\u2013L369 (2012).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10135_CR44","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353\u2013377 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10135_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo, S., Damato, A., Alfano, L. & Giordano, A. CDK9 inhibitors in acute myeloid leukemia. J. Exp. Clin. Cancer Res.: CR 37, 36 (2018).","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"key":"10135_CR46","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ceb.2008.04.008","volume":"20","author":"V Bres","year":"2008","unstructured":"Bres, V., Yoh, S. M. & Jones, K. A. The multi-tasking P-TEFb complex. Curr. Opin. Cell Biol. 20, 334\u2013340 (2008).","journal-title":"Curr. Opin. Cell Biol."},{"key":"10135_CR47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.4161\/cbt.1.4.6113","volume":"1","author":"G De Falco","year":"2002","unstructured":"De Falco, G. & Giordano, A. CDK9: from basal transcription to cancer and AIDS. Cancer Biol. Ther. 1, 342\u2013347 (2002).","journal-title":"Cancer Biol. Ther."},{"key":"10135_CR48","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1158\/1535-7163.MCT-13-0714","volume":"13","author":"TK Nguyen","year":"2014","unstructured":"Nguyen, T. K. & Grant, S. Dinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanism. Mol. Cancer Ther. 13, 662\u2013674 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"10135_CR49","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. New Engl. J. Med. 375, 1925\u20131936 (2016).","journal-title":"New Engl. J. Med."},{"key":"10135_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s12282-017-0818-4","volume":"25","author":"L Kassem","year":"2018","unstructured":"Kassem, L., Shohdy, K. S., Lasheen, S., Abdel-Rahman, O. & Bachelot, T. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer 25, 17\u201327 (2018).","journal-title":"Breast Cancer"},{"key":"10135_CR51","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1158\/1078-0432.CCR-15-1421","volume":"22","author":"W Hu","year":"2016","unstructured":"Hu, W. et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 22, 2000\u20132008 (2016).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10135_CR52","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1172\/JCI24838","volume":"115","author":"RT Schermuly","year":"2005","unstructured":"Schermuly, R. T. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Investig. 115, 2811\u20132821 (2005).","journal-title":"J. Clin. Investig."},{"key":"10135_CR53","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","volume":"127","author":"MM Hoeper","year":"2013","unstructured":"Hoeper, M. M. et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 127, 1128\u20131138 (2013).","journal-title":"Circulation"},{"key":"10135_CR54","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1164\/rccm.201001-0123OC","volume":"182","author":"HA Ghofrani","year":"2010","unstructured":"Ghofrani, H. A. et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am. J. Respir. Crit. Care Med. 182, 1171\u20131177 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10135_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-97","volume":"8","author":"D Montani","year":"2013","unstructured":"Montani, D. et al. Pulmonary arterial hypertension. Orphanet J. Rare Dis. 8, 97 (2013).","journal-title":"Orphanet J. Rare Dis."},{"key":"10135_CR56","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi, C. & Nicoletti, I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat. Protoc. 1, 1458\u20131461 (2006).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10135-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10135-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10135-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T23:41:53Z","timestamp":1671234113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-10135-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["10135"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-10135-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"12 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2204"}}